Astellas Pharma US | Changing Tomorrow | Home

Previous Pause Next

Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer

Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer Read More

U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA® (gilteritinib)

U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA® (gilteritinib) Read More

Astellas Helps Veterans Compete in 2019 Warrior Games

Astellas Helps Veterans Compete in 2019 Warrior Games Read More

The Astellas Way Blog

The Astellas Way Blog

Check out The Astellas Way Blog to hear our executives' thoughts on moments and trends in the industry and what's on the horizon for our company

1

2

3

4

News

Latest

News / Media

Aug 09, 2019

Yokohama City University, Tokyo University of the Arts and Astellas Launched Health Mock Lab. to Create New Digital Healthcare Solutions Using Gamification

News / Media

Aug 06, 2019

Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms

News / Media

Jul 17, 2019

Astellas and Frequency Therapeutics Enter into License Agreement for FX-322, a Regenerative Treatment Candidate for Hearing Loss

News / Corporate

Aug 06, 2019

Astellas Announces Appointment of David Fryrear as New Global Head of Clinical and Research Quality Assurance Organization

News / Corporate

Aug 06, 2019

Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms

News / Corporate

Jul 16, 2019

Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer